Publicaciones (40) Publicaciones de Enrique Míguez Rey

2024

  1. Efficient clinical decision-making process via AI-based multimodal data fusion: A COVID-19 case study

    Heliyon, Vol. 10, Núm. 20

2023

  1. Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort

    European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226

  2. The interaction between liver cirrhosis, infection by Streptococcus bovis, and colon cancer

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 42, Núm. 7, pp. 907-912

  3. Use of ceftaroline in complex central nervous system infections

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

2022

  1. Dalbavancin in clinical practice in Spain: A 2 year retrospective study

    JAC-Antimicrobial Resistance, Vol. 4, Núm. 6

  2. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

  3. Monoclonal antibody therapies in the management of SARS-CoV-2 infection

    Expert Opinion on Investigational Drugs, Vol. 31, Núm. 1, pp. 41-58

  4. Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV

    AIDS, Vol. 36, Núm. 5, pp. 691-695

2021

  1. Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 2, pp. 115-119

  2. Clinical Features and Outcomes of Streptococcus anginosus Group Infective Endocarditis: A Multicenter Matched Cohort Study

    Open Forum Infectious Diseases, Vol. 8, Núm. 6

  3. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  4. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

  5. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. A Contemporary Picture of Enterococcal Endocarditis

    Journal of the American College of Cardiology, Vol. 75, Núm. 5, pp. 482-494

  2. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

2019

  1. Nocardiosis pulmonar tratada con tedizolid

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 43, Núm. 6, pp. 208-210

  2. Role of age and comorbidities in mortality of patients with infective endocarditis

    European Journal of Internal Medicine, Vol. 64, pp. 63-71

  3. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2018

  1. Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse

    Journal of the American College of Cardiology, Vol. 71, Núm. 24, pp. 2731-2740

2015

  1. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: Safety analysis of a multicenter randomized trial

    Clinical Infectious Diseases, Vol. 60, Núm. 11, pp. 1642-1649